Sonobe et al. found that EGFR gene mutations are not associated with the 5-year survival rate for all patients with completely resected pathological stage I-IIIA NSCLC, but the 5-year survival rate of patients with either a stage I adenocarcinoma or large cell carcinoma who had an EGFR mutation was significantly greater than those who did not have such a mutation [51], suggesting that EGFR mutation has different impact on different types of lung cancer. This evidence concerns the gene EGFR and lung carcinoma.